What is the official ID of this bill?

The official print number for this legislation is HR 5372.

When did the legislative process begin?

The process officially started on 2023-09-08.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/hr5372/BILLS-118hr5372ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Who is the primary sponsor?

The primary sponsor is Rep. Joyce, John [R-PA-13].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.

Analysis and Potential Impact of HR 5372

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Easier Access to Lower Cost Medicines for Seniors

Q: What are the main provisions?

Key points include: Allows insurance companies to add cheaper biosimilar drugs to their formularies more quickly during the year. Permits changes to the status of more expensive reference drugs on the formulary if a cheaper biosimilar equivalent is added simultaneously. May lead to lower prescription drug costs for seniors covered by Medicare Part D, increasing access to more affordable options.

This act aims to facilitate mid-year changes to drug formularies, especially for biosimilar medications. This could allow insurance companies to introduce cheaper alternatives more quickly, potentially lowering prescription drug costs for individuals enrolled in Medicare Part D.

Key points

Allows insurance companies to add cheaper biosimilar drugs to their formularies more quickly during the year.

Permits changes to the status of more expensive reference drugs on the formulary if a cheaper biosimilar equivalent is added simultaneously.

May lead to lower prescription drug costs for seniors covered by Medicare Part D, increasing access to more affordable options.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Expanding Seniors' Access to Lower Cost Medicines Act of 2023

Print number: HR 5372

Sponsor: Rep. Joyce, John [R-PA-13]

Process start date: 2023-09-08

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Easier Access to Lower Cost Medicines for Seniors

Key Questions about Easier Access to Lower Cost Medicines for Seniors